• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Haemonetics Announces Executive Leadership Updates

    3/3/25 4:10:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email

    Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer

    BOSTON, March 3, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, Chief Operating Officer on April 7, 2025, and Roy Galvin has been appointed as the company's Executive Vice President, Chief Commercial Officer effective immediately.

    As Chief Operating Officer, Chan will direct Haemonetics' research and development as well as regulatory affairs, driving innovation and operational excellence to support the company's growth. He will also oversee Haemonetics' global manufacturing and supply chain operations. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer.

    With more than 25 years of experience in medical device and healthcare technology leadership, Chan has successfully delivered innovative solutions to market, expanded patient access with global market development, and led business transformation initiatives across large organizations. He joins Haemonetics from Medtronic plc, where he served as President of Acute Care & Monitoring, overseeing a global portfolio of airway management, patient monitoring, and connected care solutions. Prior to Medtronic, he held roles of increasing responsibility at Covidien plc (acquired by Medtronic) and DePuy Orthapaedics, Inc. (a Johnson & Johnson company).

    Galvin joined Haemonetics in 2022 as President, Global Plasma and Blood Center. As Chief Commercial Officer, he will now have responsibility for the company's Global Hospital business as well as Global Plasma and Blood Center, directing all commercialization initiatives to expand the reach and breadth of Haemonetics' full product portfolio. Galvin brings to the role extensive experience in the global healthcare technology field for hospitals and the surgical suite, with over 25 years working at Medtronic plc scaling businesses in the Neuroscience and Orthopedic markets.

    "We are executing our long-range plan to achieve exciting growth and build a foundation for sustained success. By strengthening our executive leadership with the addition of Frank Chan and an expanded role for Roy Galvin, we are well-positioned to drive the next phase of our growth," said Chris Simon.

    About Haemonetics

    Haemonetics (NYSE:HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

    Investor Contacts:









    Olga Guyette, Vice President-Investor Relations & Treasury Investor Relations







    David Trenk, Manager-Investor Relations

    (781) 356-9763







    (203) 733-4987

    [email protected]  







    [email protected]











    Media Contact:









    Josh Gitelson, Senior Director-Global Communications









    (781) 356-9776









    [email protected] 









     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-announces-executive-leadership-updates-302390394.html

    SOURCE Haemonetics Corporation

    Get the next $HAE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    12/6/2024$116.00Overweight
    Analyst
    11/8/2024$120.00Outperform → Strong Buy
    Raymond James
    9/13/2024$116.00Buy
    CL King
    9/11/2024$85.00Neutral
    BofA Securities
    9/10/2024$112.00Buy
    BTIG Research
    6/12/2024$112.00Hold → Buy
    Needham
    10/13/2022$90.00Buy
    Mizuho
    More analyst ratings

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      BOSTON, May 30, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:40 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1721260&tp_key=3096fdc651&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be availab

      5/30/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

      First fully absorbable, sutureless closure system designed for large-bore procedures aims to improve procedural efficiency and patient outcomes in structural heart interventions Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced European CE mark approval of the PerQseal® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer. Leveraging Vivasure's PerQseal technology, the PerQseal Elite vascular closure system is designed exclusively for sutureless and fully absorbable large-bore closure follow

      4/22/25 9:36:00 AM ET
      $HAE
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products

    $HAE
    SEC Filings

    See more
    • SEC Form 144 filed by Haemonetics Corporation

      144 - HAEMONETICS CORP (0000313143) (Subject)

      6/12/25 4:51:50 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Haemonetics Corporation

      DEFA14A - HAEMONETICS CORP (0000313143) (Filer)

      6/6/25 4:18:27 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Haemonetics Corporation

      DEF 14A - HAEMONETICS CORP (0000313143) (Filer)

      6/6/25 4:17:37 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care